Showing 5661-5670 of 9115 results for "".
- GlobalData: Sun Pharma's Ilumya To Face Strong Competition in the US markethttps://practicaldermatology.com/news/globaldata-sun-pharmas-ilumya-will-face-strong-competition-in-the-us-market/2457816/It’s a tough road ahead for Sun Pharma’s newly approved Ilumya, according to a new report from
- DefenAge® Skincare Trio Performs Well in New Studyhttps://practicaldermatology.com/news/defenage-skincare-trio-performs-well-in-new-study/2457818/Progenitor Biologics’ DefenAge® Skincare, a-three-step system “globally improves the visual appearance of aging skin without irritation, dryness, or inflammation,” according to new research in the
- ASDSA Applauds USPSTF Endorsement of Behavioral Counseling to Prevent Skin Cancerhttps://practicaldermatology.com/news/asdsa-applauds-uspstf-endorsement-of-behavioral-counseling-to-prevent-skin-cancer/2457820/The American Society for Dermatologic Surgery Association (ASDSA) applauds the recent US Preventive Service Task Force (USPSTF) endorsement of behavioral counseling to prevent skin cancer for individuals aged six months to 24 years
- Escalier Biosciences Closes Financing, Focuses on Psoriasishttps://practicaldermatology.com/news/escalier/2457821/Escalier Biosciences BV, a privately held biopharmaceutical company, this month closed $19 million Series B financing. The round was led by Forbion with existing investors New Science Ventures and BioGeneration Ventures (BGV) completing the round. Escalier is developing both topic
- Hydrogen Peroxide 40% Less Cytotoxic Than Cryotherapy: Studyhttps://practicaldermatology.com/news/hydrogen-peroxide-40-less-cytotoxic-than-cryotherapy-study/2457822/Hydrogen peroxide topical solution 40% (Eskata, Aclaris) is less cytotoxic to living cells and less damaging to melanocytes than cryosurgery, according to a new study led by Adam Friedman, MD, associate professor of dermatology at the GW School of Medicine and Health Sciences. <
- Did New USPSTF Recommendations on Skin Cancer Prevention Counseling Go Far Enough? AADA Reactshttps://practicaldermatology.com/news/did-new-uspstf-recommendations-on-skin-cancer-prevention-counselling-go-far-enough-aada-reacts/2457830/The U.S. Preventive Services Task Force (USPSTF) is calling for behavioral counseling to help reduce the risk of skin cancer from ultraviolet (UV) radiation in people aged 6 months to 24 years with fair skin types. The new USPSTF recommendation statement updates a 2012 recommendation on b
- Sun Pharma: FDA Approves Ilumya for Adult Psoriasishttps://practicaldermatology.com/news/sun-pharma-fda-approves-ilumya-for-adult-psoriasis/2457831/The FDA has approved Ilumya™ (tildrakizumab-asmn) from Sun Pharma for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ilumya selectively binds to the p19 subunit of IL-23 a
- Proscia Inks Agreement to Bring Deep-Learning Technology to Dermatopathologyhttps://practicaldermatology.com/news/proscia-inks-agreement-to-bring-deep-learning-technology-to-dermatopathology/2457832/Proscia Inc., creators of AI-powered digital pathology software, signed a first-of-its-kind agreement with one of the largest dermatopathology labs in the country. This agreement provides Proscia with exclusive access to pathology slides and expert pathologist ground-truth data for an arr
- First Patient Dosed in Proof-of-Concept Trial of Topical by Design JAK Inhibitor SNA-125 for Atopic Dermatitishttps://practicaldermatology.com/news/first-patient-dosed-in-proof-of-concept-trial-of-topical-by-design-jak-inhibitor-sna-125-for-atopic-dermatitis/2457839/The first patient has been dosed in Sienna Biopharmaceuticals, Inc.'s Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of atopic dermatitis and the associated pruritus. SNA-125 is designed to inhibit Janus kinase 3, or JAK3, and tropomyosin recep
- Aclaris Therapeutics Receives US Patent Covering a JAK Inhibitor for Treating Hair Loss Disordershttps://practicaldermatology.com/news/aclaris-therapeutics-receives-us-patent-covering-a-jak-inhibitor-for-treating-hair-loss-disorders/2457840/The United States Patent and Trademark Office (USPTO) issued US Patent No. 9,895,301, which is directed to methods related to the use and administration of a certain janus kinase (JAK) inhibitor for treating hair loss disorders. This newly allowed patent is owned by The Trustees of Columbia Unive